First New High Blood Pressure Drug in More Than a Decade Okayed
Tekturna acts on one of the body's key regulators of blood pressure by targeting renin.
The first new type of high blood pressure medicine in more than a decade was approved, according to Novartis. Tekturna, developed by Novartis and Speedel, is a direct renin inhibitor. Renin is an enzyme that triggers a process, which can contribute to high blood pressure.
"Renin angiotensin system activity contributes to many of the complications associated with high blood pressure," points out Marc A. Pfeffer, M.D., Ph.D., professor of medicine, Harvard Medical School and Cardiologist at Brigham & Women's Hospital. "By inhibiting this important system at its origin, renin production, a direct renin inhibitor, such as Tekturna, offers an exciting therapeutic option for treating hypertension."
Tekturna was approved for the treatment of high blood pressure as a monotherapy or in combination with other high blood pressure medications.